Opinion|Videos|March 14, 2025

Future Outlooks for CAR T in Early R/R Multiple Myeloma

Panelists discuss how chimeric antigen receptor (CAR) T-cell therapy could potentially be moved to earlier lines of treatment in relapsed/refractory multiple myeloma based on emerging trial data, improving outcomes through earlier intervention before patients develop treatment resistance.

Episodes in this series


Latest CME